Asthma used to be thought of as an entirely reversible disorder. As a consequence, our therapeutic approach to asthma has focused on symptomatic control through the alleviation of bronchospasm and the reduction of airway inflammation. It is now known, however, that this optimistic picture of the natural history of asthma is not entirely complete. A number of studies have demonstrated that asthmatics, as a group, experience an accelerated rate of respiratory functional deterioration (1, 2). This is nicely illustrated in a recent study of 17,506 people followed over a 15-year period in the Copenhagen Heart Study. In this population, the 1,095 patients with self-reported asthma experienced a greater decline in airway function (forced expiratory volume in 1 second [FEV1]) than did controls (38 mL per year vs. 22 mL per year), and the greatest rates of decline were experienced by smokers with asthma (1). Patient-to-patient variability has also been noted, with some patients acquiring a physiologic state characterized by irreversible or partially reversible airway obstruction, and others manifesting incomplete β-agonist responses and persistent airways hyperresponsiveness (AHR) even after prolonged corticosteroid therapy. The pathologic correlates and pathogenetic mechanisms responsible for these findings are incompletely understood. Recent attention has, however, been directed at the structural changes — collectively referred to as airway remodeling — in the asthmatic and normal airway. This is based on the belief that these changes are responsible, in a cause-and-effect fashion, for these adverse outcomes and for other manifestations of the asthmatic diathesis. The change that this represents in our concept of the pathogenesis of asthma and the features and pathogenesis of asthmatic airway remodeling is reviewed below.
Implicit in the “inflammation theory” of asthma is the belief that inflammation is both necessary and sufficient to account for the complex features of asthma. Although inflammation is undoubtedly a cornerstone of asthma, it is now clear that the asthmatic response is more complex. It is also clear from pathologic investigations that structural alterations exist in the asthmatic airway. Mathematical modeling studies have provided evidence that these alterations contribute to the symptoms and physiologic dysregulation seen in asthma (see below). As a result, it has been proposed that the chronic inflammation that is characteristic of the asthmatic airway leads to a remodeling response, and that the structural alterations caused by this response play an important role in generating the manifestations of the disorder. This conceptual evolution predicts that we will acquire an enhanced understanding of asthma pathogenesis when we think of asthma in the context of paradigms of injury and wound healing, as well as the traditional paradigms relevant to the interface of inflammation and airway physiology. It also suggests that studies utilizing this new perspective will identify novel targets against which therapies can be directed, and will provide an enhanced understanding of the biologic basis of the patient-to-patient variability that is encountered in this disorder.
Airway wall thickening. All components of the airway wall (inner, outer, and total) have been reported to be thickened in asthma (10, 11). Many elements contribute to this response, including an increase in airway smooth muscle; edema; inflammatory cell infiltration; glandular hypertrophy; and connective tissue deposition. Airway wall thickness is increased 50–300% in cases of fatal asthma and 10–100% in cases of nonfatal asthma (10), compared with nonasthmatic controls. In fatal asthma, the thickening is most marked in the small cartilaginous and large membranous airways. In nonfatal asthma, the thickening is more marked in small membranous airways (diameter <0.6 mm) and mid-sized airways (diameter 1–3 mm), and is less marked in the central airways. The physiologic and clinical consequences of airway wall thickening are incompletely understood. A number of studies suggest that increases in wall thickness correlate with disease severity. Mathematical modelings that incorporate morphologic and physiologic measurements made on asthmatic and nonasthmatic tissues (10, 12) have demonstrated that the thickening response can enhance the degree of luminal effacement caused by a given degree of muscle contraction, and that the magnitude of airway wall thickening is sufficient to contribute substantially to asthmatic AHR. They have also demonstrated that increased thickness of the outer wall could uncouple the airway from the distending and tethering forces of the surrounding lung parenchyma, thereby allowing greater degrees of smooth muscle contraction with less tension development and increased maximal muscle shortening. The recently popularized “perturbed equilibrium hypothesis” also suggests that wall thickening can destabilize the dynamic forces that control airway caliber, causing airway collapse (13). All in all, these studies suggest that wall thickening increases the airway narrowing caused by smooth muscle stimulation, thereby promoting bronchospasm and hyperresponsiveness to bronchospastic stimuli.
Subepithelial fibrosis. Early postmortem studies described what was believed to be thickening of the asthmatic basement membrane. Electron microscopy demonstrated that the true basement membrane, the lamina rara and densa, is normal in these tissues. The “thickening” is the result of a dense fibrotic response that occurs primarily in the lamina reticularis (4, 14, 15). This response is characterized by the enhanced accumulation of fibronectin and types I, III, and V collagens. Type IV collagen and laminin are not present in enhanced quantities. The pathophysiologic significance of subepithelial fibrosis is not clear. However, the presence of subepithelial fibrosis has been associated with disease severity and correlated with a decline in FEV1 (16, 17). In addition, significant correlations have been reported between methacholine sensitivity and the intensity of airway fibrosis (18, 19) and between subepithelial thickness and frequency and duration of asthma symptoms. These findings suggest that the fibrotic response may play a role in disease severity and in the generation of the incompletely reversible airway obstruction that is seen in some patients. They also suggest that fibrosis may lead to, or be a determinant or marker of, a pathway(s) that leads to AHR. Caution is required, however, because subepithelial fibrosis has been noted in biopsies from patients with mild asthma (14, 15) and in nonasthmatics with allergic rhinitis, and because patient populations have been reported in which asthma severity does not correlate with submucosal collagen deposition (20). Additional investigation will be required to determine if these conflicting observations address the consequences of subepithelial fibrosis or, instead, suggest that patients can acquire severe asthma through mechanisms that may or may not involve airway remodeling.
Increased myocyte muscle mass. An increase in the area of airway smooth muscle has been demonstrated in most, but not all, studies of fatal and nonfatal asthma (10). The changes that have been noted are most marked in the central airways in asthma fatalities and in the large membranous bronchioles in the nonfatal specimens. Some investigators believe that hyperplasia is the major contributor to this response (21). Others have described 2 distinct responses (22). In type I asthma, the increase in muscle mass was associated only with hyperplasia and was restricted to large central airways. In type II asthma, comparatively mild hyperplasia was seen in the large airways, and hypertrophy was detected throughout the bronchial tree, particularly in small peripheral airways (22). It is not clear if these different patterns reflect different types of injuries or different tissue or host response mechanisms. It is clear from modeling studies that either abnormality can contribute to the AHR and bronchospasm characteristic of the asthmatic diathesis (10, 12).
Myofibroblast hyperplasia. Subepithelial myofibroblast hyperplasia has been repeatedly demonstrated in asthma and models of asthmatic responses (23–25). Early studies identified these cells using antibodies against colonic pericrypt sheath cells. Subsequently, α-smooth muscle actin–negative and –positive myofibroblasts have been documented. The origin and fate of these cells is not fully understood. Cells with this phenotype appear quickly after antigen challenge, possibly implying a quiescent precursor cell that acquires myofibroblastic features without dividing (25). Myofibroblasts are major producers of collagenous and noncollagenous matrix molecules. They may serve a similar role in asthma, because the number of myofibroblasts present in the submucosa correlates with subepithelial collagen deposition (24).
Mucus metaplasia. Mucus hypersecretion, epithelial hypertrophy, mucus metaplasia, and airway obstruction due to bronchial mucus plugging are well-documented features of chronic asthma and status asthmaticus (26, 27). In humans, subepithelial glands are the major source of airway mucus. Morphometric studies demonstrated that the area of mucus glands is increased in fatal and nonfatal asthma. Similarly, the area of the airway epithelium is increased in asthmatic airways (10), and mucus occupies a higher percentage of the lumen of the central airways in asthma fatalities than in controls (26). Epithelial hypertrophy and airway mucus can contribute to the airway obstruction seen in asthma. Liquid and mucus on the airway surface can also amplify the effects of muscle shortening and increase the surface tension at the air-liquid interface, thereby adding to the forces that tend to narrow the airway.
Fibrosis is a dynamic process that involves the balance of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). MMP-9 is found in exaggerated quantities in sputum and biopsies from patients with asthma (30, 31). MMP-8 is the major MMP found at sites of normal wound healing, and is produced and activated in an exaggerated fashion in nonhealing wounds — an intriguing paradigm for the asthmatic airway. TIMP-1 is also present in exaggerated quantities in sputum and biopsies from patients with asthma. The levels of TIMP-1 correlate with asthmatic airway obstruction, and the exaggerated production of TIMP-1 may participate in the generation of asthmatic airway fibrosis (31, 32). In addition, in some reversible fibrotic disorders, the resolution of fibrosis is temporally associated with a marked decrease in TIMP-1 and TIMP-2 expression.
IL-6–type cytokines. The IL-6–type cytokine family contains IL-6, IL-11, cardiotropin-1, oncostatin-M, and ciliary neurotropic factor. These cytokines have overlapping effector profiles, similar 3-dimensional structures, and all use the promiscuous gp130 molecule in their multimeric receptor complexes.
IL-6. IL-6 is a pleiotropic molecule that has been repeatedly found in exaggerated quantities in biologic fluids and tissues from patients with asthma and models of the asthmatic diathesis. Its ability to stimulate T and B cells and contribute to the development of Th2-dominated inflammation led to the speculation that it plays a role in the generation and/or perpetuation of asthmatic tissue inflammation. However, IL-6 also has anti-inflammatory and cytoprotective activities, and is the major stimulator of the acute-phase response. This led to the belief that IL-6 may also be a general-alarm signal that marshals protective responses that serve to diminish tissue inflammation and injury. An indication that IL-6 might participate in airway remodeling came from studies from our laboratories that used the CC10 promoter to overexpress IL-6 in the murine airway (35). These and subsequent studies demonstrated that IL-6 causes impressive subepithelial fibrosis, with collagen deposition and the enhanced accumulation of α-smooth muscle actin–containing stromal cells (Table 1). IL-6 did not cause tissue eosinophilia, mucus metaplasia, or AHR upon methacholine challenge.
IL-11. IL-11 is a multifunctional molecule that stimulates thrombopoiesis, induces the production of TIMP-1, and regulates bone metabolism. Studies from our laboratory demonstrated that IL-11 is produced by a variety of lung stromal cells, including airway and alveolar epithelial cells, fibroblasts, and airway myocytes, in response to TGF-β, IL-1, asthma-associated viruses, histamine, and eosinophil major basic protein (36, 37). Our studies also demonstrated that the transgenic overexpression of IL-11 causes an airway phenotype characterized by (a) subepithelial fibrosis; (b) the enhanced deposition of types III and I, but not type IV, collagens; (c) the enhanced accumulation of fibroblasts, myofibroblasts, and myocytes; and (d) baseline airway obstruction and AHR upon methacholine challenge (23). Tissue eosinophilia and mucus metaplasia are not features of the lungs of these animals. The validity of the transgenic approach was confirmed in studies that applied immunohistochemistry and in situ hybridization to biopsies from human asthmatics (38). These investigations demonstrated that IL-11 mRNA and protein can be detected in large quantities in biopsies from patients with severe asthma, but not in biopsies from patients with mild asthma or from normals. In these tissues, IL-11 is expressed in epithelial cells and eosinophils. Further insight was obtained from studies utilizing the IL-11–overexpressing transgenic mice in models of airway inflammation and lung injury. These studies demonstrated that IL-11 inhibits the acute eosinophilic response and Th2 gene expression induced by sensitization and challenge with the aeroallergen ovalbumin. When viewed together, the fibrogenic and anti-inflammatory effects of IL-11 suggest that IL-11 can be a healing molecule in the airway.
Th2 cytokines. Th2-dominated inflammation is a cornerstone of the asthmatic diathesis. It is thus tempting to speculate that Th2 cytokines play a key role in asthmatic airway remodeling. Transgenic overexpression studies from our laboratories and others’ provide in vivo support for this contention. The CC10-driven overexpression of IL-13 in the lung/airway caused a profound phenotype characterized by eosinophilic and mononuclear inflammation, with mucus metaplasia, subepithelial fibrosis, airway obstruction, and AHR (39) (Table 1). Similarly, the overexpression of IL-9 and IL-4 caused a mixed mononuclear and eosinophilic inflammatory response (40, 41), and IL-5 caused impressive tissue eosinophilia (42). IL-4, IL-5, and IL-9 caused extensive mucus metaplasia, and IL-9 and IL-5 caused subepithelial fibrosis and AHR (40–42). The data on IL-4 is less impressive, with a mild fibrotic response being reported by some, but not all, investigators (41, 43). At present, prominent muscle changes have not been described in any of these Th2 cytokine–overexpression systems.
Summary: transgenic overexpression modeling. Transgenic overexpression modeling has proven to be a powerful method for defining and comparing the in vivo effector functions of asthma-relevant molecules. An adequate number of mediators have now been studied using this methodology to allow remodeling paradigms to begin to be elucidated. For example, the IL-6–type cytokines cause prominent airway fibrosis, with prominent myocyte and myofibroblast abnormalities. In the case of IL-11, airway obstruction and AHR are also noted. Airway eosinophilia and mucus metaplasia are not induced by these moieties. In contrast, the Th2-type cytokines cause mixed eosinophilic and mononuclear inflammatory responses, prominent mucus metaplasia, and less impressive airway fibrosis. In addition, smooth muscle abnormalities have not been described. These observations identify candidate molecules that might mediate the individual manifestations of the remodeling response. More importantly, they demonstrate that, to date, no single mediator has been able to recapitulate all of the features described in remodeled asthmatic airways. This suggests that the remodeling response in the asthmatic airway is generated through the concerted actions of multiple mediators, and that a variety of interventions will be required to modulate the many facets of this complex tissue reaction.
Knowledge of the reversibility of the airway remodeling phenotype is also essential. Surprisingly, the natural history of airway remodeling is poorly understood. Some studies have demonstrated that subepithelial fibrosis is unchanged over time, both in the presence and absence of steroid therapy. This has led to the statement that the structural changes, including muscle alterations and fibrosis, are “essentially irreversible” (45). However, others have reported that steroids decrease subepithelial type III collagen deposition. In addition, after cessation of exposure, patients with isocyanate-induced asthma manifest decreases in subepithelial fibrosis and in fibroblast, mast cell, and lymphocyte numbers (46). It is not known if these divergent results reflect different types of injuries, different mechanisms of tissue remodeling, or variations in host response.